Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from Senzime AB ( (SE:SEZI) ) is now available.
Senzime AB has completed the first tranche of its directed share issue, successfully allocating 22,250,000 out of 23,300,000 shares, resulting in a capital increase of approximately MSEK 102.38. This move, involving new and long-term institutional investors, aims to bolster the company’s financial standing and expand its shareholder base, with the second tranche pending approval at an extraordinary general meeting.
More about Senzime AB
Senzime is a leading medical device company based in Uppsala, Sweden, specializing in precision-based monitoring systems that enhance perioperative patient safety. Their flagship product, the TetraGraph® system, is widely used for accurate neuromuscular transmission monitoring during surgeries, ensuring precise dosing of paralytic drugs. Senzime is publicly traded on the Nasdaq Stockholm Main Market and cross-traded on the US OTCQX Market.
Average Trading Volume: 271,043
Current Market Cap: SEK732.5M
See more insights into SEZI stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue